🔎 Trials Near Me

Akèy › Adenokasinom Ezofajyen › Michigan

Etid klinik pou Adenokasinom Ezofajyen nan Michigan

9 etid pou Adenokasinom Ezofajyen ap chèche patisipan nan sit nan Michigan.

Vil nan Michigan

Tèks ofisyèl etid la (Anglè)

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • ak 21 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06203600

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  • MyMichigan Medical Center Gratiot, Alma
  • MyMichigan Medical Center Alpena, Alpena
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • ak 61 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT05677490

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

  • University of Michigan Rogel Cancer Center, Ann Arbor
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06732388

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

  • University of Michigan, Ann Arbor
Ap rekrite
Laj 18 a 89 · Tout sèks · Mizajou Sep 11, 2026 · NCT05753748

Obeticholic Acid for Prevention in Barrett's Esophagus

  • University of Michigan Rogel Cancer Center, Ann Arbor
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT04939051

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

  • Henry Ford Health System, Detroit
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT06657144

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Nov 5, 2025 · NCT05563766

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.